For example, one possible B cell targeting therapy involves the use of B-cell Activating Factor (BAFF) antagonists as BAFF deficiency or inhibition ameliorates obesity-induced inflammation in mice (136, 143). Here, TNFSF13B is linked to obesity due to melanocortin 4 receptor deficiency.